Skip to main content

Table 2 Chemotherapy dose modifications for hepatic toxicity

From: Chemoradiotherapy with concurrent durvalumab for the palliative treatment of oligometastatic oesophageal and gastrooesophageal carcinoma with dysphagia: a single arm phase II clinical trial (PALEO, sponsored by the Australasian Gastro-Intestinal Trials Group)

Hepatic toxicity

Carboplatin

week 2 dose

Paclitaxel

week 2 dose

Alanine transferase >3x ULN

No dose change

Withhold

Aspartate transferase >3x ULN

No dose change

Withhold

Total bilirubin > 1.5x ULN

No dose change

Withhold

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us